Mestag Therapeutics congratulates Founder Professor David A. Tuveson upon his appointment as 2021 President of The American Association for Cancer Research

April 12, 2021

Cambridge, UK, April 12, 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today welcomed the appointment of Professor David A. Tuveson, MD, PhD, FAACR, as 2021 President of The American Association for Cancer Research (AACR).

Professor Tuveson, a world-renowned physician-scientist whose basic and translational research focuses on the biology of pancreatic cancer and on identifying new approaches for diagnosing and treating the disease, is a key founding investigator of Mestag and serves on the company’s Scientific Advisory Board.

The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

“Mestag was created by leading scientists in fibroblast biology across inflammatory disease and cancer who have helped to create a new framework for our understanding of fibroblasts in disease”, said Susan Hill, PhD, Chief Executive Officer of Mestag. “Professor Tuveson’s work in pancreatic cancer has significantly progressed the field in oncology and identified key fibroblast populations. His appointment today as President of the AACR is testament to his exceptional standing in the oncology community. We congratulate David on his appointment and are proud to have him as a founder of our Company.”

As well as jointly founding Mestag and serving on its Scientific Advisory Board, Professor Tuveson is director of the Cold Spring Harbor Laboratory Cancer Center in Cold Spring Harbor, New York, where he is also the Roy J. Zuckerberg Professor of Cancer Research. Additionally, he is chief scientist for the Lustgarten Foundation in Woodbury, New York, the largest pancreatic cancer research philanthropic organization. He also serves as a medical staff affiliate at Memorial Sloan Kettering Cancer Center in New York and works closely with the Cancer Institute at Northwell Health on Long Island. Additionally, Professor Tuveson serves on the Board of Scientific Advisors of the National Cancer Institute.

Mestag’s mission is to develop impactful new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and cancer.

ENDS

Enquiries:

JW Communications

Julia Wilson

Tel: +44 (0)7818 430877

About Mestag:

Mestag was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer. We develop impactful therapies for patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. Our founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology Professor Michael Brenner (Brigham and Women’s Hospital and Harvard Medical School), Professor Chris Buckley (Kennedy Institute, University of Oxford), Professor David Tuveson (Cold Spring Harbor Laboratory and President of AACR), Professor Soumya Raychaudhuri (Harvard Medical School and Broad Institute) and Professor Mark Coles (Kennedy Institute, University of Oxford).

The Mestag team is progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag’s investors are SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. and the Company is headquartered in Cambridge, UK.  For more information, please visit www.mestagtx.com.